# SMART ligation-free tools for sequencing coding and non-coding RNA from low input samples



Nathalie Bolduc\*, Simon Lee, Michael Wu, and Andrew Farmer

Takara Bio USA, Inc., Mountain View, CA 94043, USA \*Corresponding Author: Nathalie\_Bolduc@takarabio.com

#### **Abstract**

Small and long non-coding RNAs play a major role in the regulation of gene expression and disease. Obtaining an accurate portrait of their expression levels from small sample inputs carries potential for both the fulfillment of basic research objectives and the development of novel therapeutics and clinical diagnostic solutions. Towards this end, we have built upon the sensitivity of our SMART® technology to develop the SMARTer® Stranded Total RNA-Seq Kit - Pico Input Mammalian (Pico kit). The Pico kit relies on random priming to synthesize cDNA from both polyadenylated and non-polyadenylated RNA, thus ensuring the capture of the non-coding RNA fraction. In addition, we developed a novel technology, ZapR, which allows for the removal of ribosomal RNA (rRNA)-derived cDNA after reverse transcription and library amplification. While our original Pico kit could accommodate inputs ranging from 250 pg to 10 ng of purified total RNA, we sought to expand the capabilities of this technology to accommodate intact cells and improve the kit's overall sensitivity and sequencing performance. While the Pico kit enables strand-specific transcriptome analysis from very low amounts of total RNA or cells, it does not allow for the analysis of small RNAs, such as miRNAs, piRNAs, etc. To address this limitation, we developed the SMARTer smRNA-Seq Kit for Illumina<sup>®</sup>, a novel, ligation-free approach for the preparation of small RNA sequencing libraries that leverages RNA 3' polyadenylation followed by cDNA synthesis and template switching. This approach minimizes sample representation bias and is sensitive enough to accommodate inputs of as little as 1 ng of total RNA. The combination of the SMARTer Stranded Total RNA-Seq Kit - Pico Input Mammalian and the SMARTer smRNA-Seq Kit for Illumina provides a complete toolkit for accurate, sensitive, and reproducible detection of small and long non-coding RNAs with fast and easy workflows.

# 1a SMARTer Stranded Total RNA-Seq Kit v2 - Pico Input Mammalian: Workflow




Figure 1. Schematic of technology used by the SMARTer Stranded Total RNA-Seq Kit v2 - Pico Input Mammalian. SMART technology is used in this ligation-free protocol to preserve strand-of-origin information. Random priming allows for the generation of cDNA from all RNA fragments in the sample, including rRNA. When SMARTScribe™ Reverse Transcriptase (RT) reaches the 5′ end of an RNA template, the enzyme's terminal transferase activity adds a few non-templated nucleotides (shown as Xs) to the 3′ end of the cDNA. The Pico v2 SMART Adapter base-pairs with the non-templated nucleotides, creating an extended template that enables the RT to continue cDNA synthesis and add a priming site for subsequent PCR amplification. In the next step, a first round of PCR amplification (PCR 1) adds full-length Illumina adapters, including barcodes. Ribosomal cDNA (originating from rRNA) is then cleaved by ZapR in the presence of mammalian-specific R-Probes. This process leaves library fragments originating from non-rRNA molecules untouched, with priming sites available on both 5′ and 3′ ends for further PCR amplification. Final libraries are compatible with sequencing on any Illumina platform.

Takara Bio USA. Inc.

Takara Bio USA, Inc.
United States/Canada: +1.800.662.2566 • Asia Pacific: +1.650.919.7300 • Europe: +33.(0)1.3904.6880 • Japan: +81.(0)77.565.6999

For Research Use Only. Not for use in diagnostic procedures.

© 2017 Takara Bio Inc. All Rights Reserved. All trademarks are the property of Takara Bio Inc. or its affiliate(s) in the U.S. and/or other countries or their respective owners. Certain trademarks may not be registered in all jurisdictions. Additional product, intellectual property, and restricted use information is available at takarabio.com.

# 1b SMARTer Stranded Total RNA-Seq Kit v2 - Pico Input Mammalian: Results

Sequencing alignment metrics for varying input amounts of mouse brain total RNA								
Input amount	50 ng	10 ng	1 ng	250 pg				
Total number of reads	13,983,286	12,572,360	13,948,522	12,025,520				
Number of transcripts (FPKM ≥1)	12,311	12,251	12,113	11,976				
Proportion of total reads (%):								
Exonic	26.3	25.3	25.8	24.4				
Intronic	40.9	40.1	41.0	39.6				
Intergenic	9.6	9.7	9.9	9.6				
rRNA	10.1	13.0	11.3	14.4				
Mitochondrial	6.9	5.9	5.6	5.4				
Duplicate rate (%)	17.9	19.6	38.9	56.0				
Mapping to IncRNA:								
Proportion of total reads (%)	11.3	11.7	11.1	11.6				
Number of transcripts (TPM ≥1)	10,647	10,363	10,153	9,372				

Table 1. Evaluating the performance of the SMARTer Stranded Total RNA-Seq Kit v2 - Pico Input Mammalian across input amounts. Libraries were generated using the indicated amounts of mouse brain total RNA and sequenced on an Illumina NextSeq™ 500 instrument (2 x 75 bp). Bioinformatic analyses were performed using CLC Genomics Workbench. Reads were trimmed and mapped to rRNA and the mitochondrial genome. Unmapped reads were then mapped to the mouse (mm10) genome with RefSeq masking. For analysis of IncRNA, reads were trimmed and mapped against the "Long non-coding RNA transcript sequences" Fasta file included in the GENCODE m12/m38.p5 release (containing 14,610 loci transcripts). FPKM and TPM refer to "fragments per kilobase of transcript per million mapped reads" and "transcripts per kilobase million," respectively.




Figure 2. Evaluating the reproducibility of data generated with the SMARTer Stranded Total RNA-Seq Kit v2 - Pico Input Mammalian across input amounts. Libraries were generated using the indicated amount of mouse brain total RNA, and then sequenced and analyzed as described above. Correlations in gene expression for both whole transcriptome (Panel A) and IncRNA (Panel B) data were subject to statistical analysis and are presented using scatterplots (FPKM and TPM values, respectively). For both data types, strong correlations are observed across technical replicates of the same input, but also across the low (250 pg) and high (50 ng) input range of the kit.

#### **Conclusions**

SMART technology is a very sensitive and versatile tool for NGS library preparation from coding and non-coding RNAs of all sizes.

#### Whole transcriptome/IncRNA analysis:

- SMARTer Stranded technology, included in the new SMARTer Stranded Total RNA-Seq Kit v2 Pico Input Mammalian, is well-suited for RNA-seq applications that require exceptional sensitivity and strand-of-origin information, such as research involving IncRNAs.
- The new v2 workflow is very similar to that of the original SMARTer Stranded Total RNA-Seq Kit Pico Input Mammalian, but provides a more user-friendly experience, and importantly, significantly higher performance on all Illumina sequencing platforms.

#### smRNA analysis:

- Using RNA 3' polyadenylation and SMART template-switching technology, we developed a small RNA library preparation method that provides greater accuracy than approaches involving adapter ligation.
- In addition to capturing miRNAs, the SMARTer smRNA-Seq Kit for Illumina enables analysis of piRNAs, snoRNAs, snoRNAs, snRNAs, etc.

## 2a SMARTer smRNA-Seq Kit for Illumina: Overview




Figure 3. Schematic of technology used by the **SMARTer smRNA-Seq Kit for Illumina.** SMART technology is used in a ligation-free workflow to generate sequencing libraries for Illumina platforms. Input RNA is first polyadenylated in order to provide a priming sequence for an oligo(dT) primer (3' smRNA dT Primer). When the MMLV-derived PrimeScript™ Reverse Transcriptase (RT) reaches the 5' end of each RNA template, it adds non-templated nucleotides which are bound by the SMART smRNA Oligoenhanced with locked nucleic acid (LNA) technology for greater sensitivity. In the template-switching step, PrimeScript RT uses the SMART smRNA Oligo as a sequence (purple) to the 3' end of each first-strand cDNA molecule. In the final step, full-length Illumina adapters (including indexes for sample multiplexing) are added during PCR amplification.

### 2b SMARTer smRNA-Seq Kit for Illumina: Results




Figure 4. Accuracy and reproducibility of data generated with the SMARTer smRNA-Seq Kit for Illumina. Panel A. To gauge the accuracy of the SMARTer approach, sequencing libraries were generated from an equimolar pool of 963 synthetic miRNAs (miRXplore Universal Reference) using the SMARTer smRNA-Seq Kit for Illumina (1 ng input; purple), or a small RNA-seq kit from a different vendor (Competitor N) employing an adapter-ligation method (100 ng input; blue). miRNA expression levels (Y-axis, log scale) were normalized, resulting in an expected expression level equal to 1 for each miRNA, and a 2-fold cutoff was assigned both above and below the expected expression level (indicated by two horizontal lines). For visualization purposes, miRNAs are ranked along the X-axis in order of expression level. Panel B. To assess the reproducibility of data generated with the SMARTer approach, sequencing libraries were generated in parallel from the indicated input amounts of the miRXplore Universal Reference using the SMARTer smRNA-Seq Kit for Illumina. Expression levels of miRNAs identified for each library were quantified and plotted on correlation diagrams, and Pearson and Spearman correlation coefficients were calculated.

RNA source	Placenta		Brain		Spleen	
small RNA <200 nt (% of total RNA)	13%		5%		2%	
Input amount	2 μg	1 ng	<b>2</b> μg	1 ng	2 μg	1 ng
Total number of reads	4,342,213	4,744,519	4,764,574	4,275,787	3,796,263	4,254,142
Proportion of reads discarded	15.1%	24.7%	23.2%	31.8%	38.6%	32.2%
Proportion of reads mapped to GENCODE	76.5%	65.4%	68.1%	56.9%	53.7%	56.1%
miRNA mapping (miRBase)						
Number of miRNA reads	485,331	509,129	657,282	340,814	326,870	353,553
Proportion of total reads	11.2%	10.7%	13.8%	8.0%	8.6%	8.3%
Unique miRNAs detected	260	263	286	253	198	221
Number of miRNAs in common	247		243		187	
Proportion of miRNAs in common	89%		82%		81%	
Other small RNA mapping (pro	portion of	total read	ds, %)			
piRNA	3.5	3.7	8.9	5.1	4.1	3.1
snoRNA	1.0	0.7	0.8	0.5	1.1	1.3
snRNA	2.1	1.1	1.2	0.8	0.7	0.9
tRNA	2.1	3.4	4.0	2.9	0.9	0.9
Other RNAs (proportion of total	al reads, %	o)				
rRNA (5, 5.8, 18, and 28S)	19.2	12.8	12.1	10.1	14.9	13.8




Table 2. Evaluating the performance of the SMARTer smRNA-Seq Kit for Illumina across RNA input types and amounts. Sequencing libraries were generated from 1 ng and 2 µg of human placenta, brain, and spleen total RNA. The miRNA fraction, corresponding to a final library size of about 175 bp, was enriched prior to sequencing using a BluePippin instrument. Following trimming, reads were mapped either to the GENCODE dataset (for overall mapping), or to specific small RNA datasets, as indicated. Only miRNAs represented by at least five reads were included in count data for the number of miRNAs detected.

Figure 5. Reproducibility of **SMARTer small RNA-seq data** generated from human brain total RNA samples. From the sequencing data presented in **Table 2**, miRNA expression levels were quantified and plotted on correlation diagrams, and Pearson Spearman correlation coefficients were calculated. **Panel A.** Correlation of miRNA expression levels for experimental replicates involving 1 ng inputs. Panel B. Correlation of miRNA expression levels for 2 µg vs. 1 ng inputs.

